Evaluation of NDRG2 gene expression in primary papillary thyroid carcinoma and in metastases of this neoplasm to regional lymph nodes.
BACKGROUND
At present, researchers' attention has been concentrating on NDRG2 (N-Myc downstream-regulated gene 2) as a new gene candidate in the development and progression of papillary thyroid carcinoma (PTC). NDRG2, together with NDRG1, NDRG3 and NDRG4 are members of the NDRG family, a new class of genes, inhibited by N-Myc oncogene.


OBJECTIVE
The aim of our study was to evaluate NDRG2 mRNA expression in the primary PTC and its metastases to regional lymph nodes.


METHODS
Postoperative tissue and macroscopically changed lymph nodes of sixteen (16) patients with PTC constituted the studied material. In this group, metastases of the cancer to regional lymph nodes were confirmed histopathologically in 8 cases. Quantitative evaluation of NDRG2 mRNA expression was performed by the real-time polymerase chain reaction (real-time PCR) method.


RESULTS
The mean values of NDRG2 mRNA expression in the primary tumour tissues were statistically significantly lower vs. the levels of NDRG2 mRNA expression in macroscopically unchanged thyroid tissue (p < 0.0001). A comparison of the mean NDRG2 mRNA expression of primary tumours and that of their metastases to regional lymph nodes did not demonstrate any statistical differences (p > 0.05). A positive correlation was observed between NDRG2 mRNA expression in primary tumour cells and in the cancer metastases to lymph nodes (Rs = 0.7857; p < 0.05). Factors, such as age, sex, tumour stage in TNM system, were of no significance for NDRG2 mRNA expression level (p > 0.1).


CONCLUSIONS
The results of our study demonstrated decreased NDRG2 mRNA expression levels in PTC, when compared to macroscopically unchanged thyroid tissue, which may point to the potential role of NDRG2 in the development and progression of cancer in question.
Mordalska
Anna
A
Department of Endocrinology and Metabolic Diseases, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland. alewin@csk.umed.lodz.pl.
Latek
Joanna
J
Ferenc
Tomasz
T
Pomorski
Lech
L
Gałecka
Elzbieta
E
Zygmunt
Arkadiusz
A
Lewiński
Andrzej
A
Oncogene. 2006 Jan 5;25(1):111-21
16247483
BMC Cancer. 2007 Oct 12;7:192
17935612
World J Gastroenterol. 2004 Dec 1;10(23):3518-21
15526377
Oncogene. 2008 Oct 27;27(50):6462-72
18955973
Arch Surg. 2005 Oct;140(10):940-5
16230542
Lancet. 2003 Feb 8;361(9356):501-11
12583960
Am J Surg Pathol. 2003 Feb;27(2):159-66
12548161
Endocr J. 2010;57(6):523-31
20379035
Int J Cancer. 2003 Sep 1;106(3):342-7
12845671
Biol Pharm Bull. 2008 Jul;31(7):1316-20
18591767
Mod Pathol. 2008 May;21 Suppl 2:S37-43
18437172
Biochem Biophys Res Commun. 2007 Jun 22;358(1):164-9
17470364
Am J Surg Pathol. 2006 Feb;30(2):216-22
16434896
J Cancer Res Clin Oncol. 2005 Mar;131(3):191-8
15592684
Mol Cell Biochem. 2002 Jan;229(1-2):35-44
11936845
Endocr Regul. 2000 Jun;34(2):99-113
10991553
Nucleic Acids Res. 2008 Sep;36(16):5335-49
18689861
Exp Mol Med. 2007 Dec 31;39(6):705-14
18160841
BMC Cancer. 2008 Oct 22;8:303
18940011
Cancer Res. 2005 Aug 15;65(16):7121-6
16103061
Acta Biochim Biophys Sin (Shanghai). 2008 Jul;40(7):625-35
18604454